Table 9.
Liver Function Before and After DEB-TACE Treatment (440 DEB-TACE Records)
| Baseline | 1 Week After DEB-TACE | 1–3 Months After DEB-TACE | p Value* | p Value† | |
|---|---|---|---|---|---|
| ALB abnormal | 177/438 (40.4) | 208/379 (54.9) | 168/399 (42.1) | <0.001 | 0.619 |
| TP abnormal | 114/438 (26.0) | 192/379 (50.7) | 94/399 (23.6) | <0.001 | 0.409 |
| TBIL abnormal | 104/437 (23.8) | 179/379 (47.2) | 100/399 (25.1) | <0.001 | 0.671 |
| TBA abnormal | 145/407 (35.6) | 118/352 (33.5) | 143/373 (38.3) | 0.124 | 0.433 |
| ALT abnormal | 93/438 (21.2) | 232/379 (61.2) | 93/399 (23.3) | <0.001 | 0.471 |
| AST abnormal | 166/435 (38.2) | 243/373 (65.1) | 162/397 (40.8) | <0.001 | 0.435 |
| ALP abnormal | 169/431 (39.2) | 168/372 (45.2) | 211/396 (53.3) | 0.088 | <0.001 |
Data are presented as count/total with percent in parentheses. Comparison among groups was determined by chi-square test. A value of p < 0.05 was considered significant. Analysis was based on 440 DEB-TACE records. *p Value of liver function-related biochemical indexes of patients from baseline to 1 week posttreatment. #p Value of liver function-related biochemical indexes of patients from baseline to 1–3 months posttreatment.